Pomerantz Law Firm Probes Potential Securities Fraud At Exelixis, Inc. - Investors Alerted

Investigating Securities Fraud Claims Against Exelixis, Inc.

Pomerantz LLP, a well-regarded law firm specializing in class-action securities litigation, has announced an investigation concerning potential securities fraud claims involving Exelixis, Inc., a biotechnology company publicly traded on NASDAQ under the ticker symbol EXEL. Investors who feel they may have been affected are encouraged to reach out for more information.

Context of the Investigation

On July 28, 2025, Exelixis revealed its financial results for the second quarter of 2025, which fell short of investor expectations. Specifically, the company reported net product revenues for its key drug, cabozantinib, were approximately 2% below the consensus estimate, amounting to around $531.3 million. Furthermore, Exelixis announced that it would not be moving forward with the phase 3 trial of the STELLAR-305 study concerning advanced squamous cell carcinoma due to emerging competitive pressures and alterations in commercial opportunities.

The announcement came as a shock to many, leading to a significant decline in Exelixis’s share price, which plummeted by $7.45 (or 16.78%), closing at $36.94 per share the following day. Such a drastic reduction raises concerns about the integrity of the information provided to investors.

Concerns Over Corporate Governance

The key issue at hand is whether Exelixis and its management, including certain officers and directors, engaged in practices that may constitute securities fraud or other unlawful business behaviors. These claims arise from the significantly lower-than-expected revenues and the abrupt decision to halt progress on important clinical trials, which are vital to a biotech company's future prospects.

As the investigation unfolds, Exelixis investors are reminded of their rights and encouraged to participate in the upcoming class action. Those with questions regarding their investments in Exelixis can contact Danielle Peyton at Pomerantz LLP for detailed information about the process and any potential compensation.

Pomerantz Law Firm’s Legacy

Founded nearly a century ago by Abraham L. Pomerantz, widely recognized as a pioneer in the field of class action lawsuits, Pomerantz LLP has built a storied reputation for advocating for investors. The firm has achieved multimillion-dollar settlements on behalf of its clients, focusing primarily on victims of securities fraud, breaches of fiduciary duty, and corporate misconduct.

As a firm driven by the mission to protect the rights of investors, Pomerantz continues to operate from multiple large offices worldwide, including locations in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv.

Conclusion

If you are an investor in Exelixis, it is crucial to stay informed about this investigation, as the implications of any findings could be significant. The ongoing developments regarding Exelixis's operational conduct may have legal consequences, and affected investors must be vigilant about their investments. For those interested in joining the class action or seeking counsel, direct your queries to Pomerantz LLP promptly.

Contact Information:
Danielle Peyton
Pomerantz LLP
Email: [email protected]
Phone: 646-581-9980 extension 7980

For further updates on this inquiry and to monitor the progress, please visit Pomerantz Law Firm's official website.